Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin + metformin fixed-dose combination in drug-naïve type 2 diabetes mellitus (factorial study)
CTR20132231Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linagliptin + metformin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Sep 2014; status: completed.
02
Drugs
linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20132231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132231.